Basic Information
| LncRNA/CircRNA Name | MIR100HG |
| Synonyms | MIR100HG, AGD1, linc-NeD125, lncRNA-N2 |
| Region | GRCh38_11:122028327-122556721 |
| Ensemble | ENSG00000255248 |
| Refseq | NR_024430 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | cetuximab | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR etc. |
| Sample | cell lines |
| Expression Pattern | up-regulated |
| Function Description | MIR100HG, miR-100 and miR-125b overexpression was also observed in cetuximab-resistant colorectal cancer and head and neck squamous cell cancer cell lines and in tumors from colorectal cancer patients that progressed on cetuximab. miR-100 and miR-125b coordinately repressed five Wnt/B-catenin negative regulators, resulting in increased Wnt signaling, and Wnt inhibition in cetuximab-resistant cells restored cetuximab responsiveness. Our results describe a double-negative feedback loop between MIR100HG and the transcription factor GATA6, whereby GATA6 represses MIR100HG, but this repression is relieved by miR-125b targeting of GATA6. These findings identify a clinically actionable, epigenetic cause of cetuximab resistance. |
| Pubmed ID | 29035371 |
| Year | 2017 |
| Title | lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/B-catenin signaling |
External Links
| Links for MIR100HG | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |